Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight

As Glenmark Pharmaceuticals Limited pivots from its generics-heavy legacy toward oncology-focused biotech innovation, its investigational therapy ISB 2001 has become a strategic turning point. Developed by Ichnos Glenmark Innovation (IGI), the company’s biotech subsidiary, ISB 2001 recently received Fast Track designation from the U.S. Food and Drug Administration (FDA) in April 2025. This recognition, targeted at patients with relapsed or refractory multiple myeloma (r/r MM), significantly raises the international profile of both the molecule and Glenmark itself. For a company long associated with branded generics and emerging markets, the shift toward immuno-oncology represents a structural repositioning, not just an incremental R&D update.

What Is ISB 2001 and Why Is It Important?

ISB 2001 is a trispecific T-cell engager antibody designed to attack multiple myeloma cells on three immunological fronts. It binds to the BCMA and CD38 antigens found on malignant plasma cells, while simultaneously activating CD3 receptors on T-cells, thereby triggering targeted immune destruction of tumor cells. Developed on IGI’s proprietary BEAT platform, the molecule’s design supports robust manufacturability and efficient multispecific binding without the limitations of traditional bispecific structures. This architecture allows ISB 2001 to address a critical limitation in current therapies—antigen escape, wherein cancer cells mutate or lose antigen targets to evade treatment.

The therapy has already demonstrated encouraging early clinical efficacy. At the 66th American Society of Hematology (ASH) Annual Meeting in December 2024, ISB 2001 posted an Overall Response Rate (ORR) of 75% in a 20-patient cohort of heavily pretreated r/r MM patients. The data indicated deep and durable responses, with some patients achieving minimal residual disease-negative complete responses. Equally important, the safety profile showed no dose-limiting toxicities, minimal neurotoxicity, and a manageable rate of cytokine release syndrome. These early signs suggest that ISB 2001 may become a compelling option for patients who have exhausted current standards like CAR-T cell therapies and CD38-targeting antibodies.

How Does ISB 2001 Compare with Global Peers in Oncology?

The global market for multiple myeloma therapies, valued at approximately $23.5 billion in 2023, is expected to cross $33 billion by 2030. This expansion reflects not only an aging population but also a rising number of patients relapsing after first-line treatments. Leading therapeutics in this space include CAR-T therapies such as Carvykti by Johnson & Johnson and Legend Biotech, and bispecific antibodies like Blenrep from Amgen. However, CAR-T treatments face serious barriers to scalability, including high cost, complex manufacturing, and long patient wait times. ISB 2001, by contrast, is an off-the-shelf solution designed for broader accessibility and faster clinical deployment.

In comparison to its global competitors, ISB 2001’s trispecific configuration offers a potent counter to tumor cell resistance. The drug simultaneously targets two antigens on cancer cells, reducing the risk of escape and delivering more consistent immune engagement. Preclinical studies and early human data suggest superior cytotoxicity even in samples from patients who had relapsed after CD38 and BCMA therapies. If subsequent trials validate this trend, ISB 2001 could not only enter the market as a new therapy but possibly reset treatment protocols in this space. Glenmark’s positioning as a mid-sized player with an innovation-first asset makes this case even more unique.

What’s Glenmark’s Broader Biotech Strategy Through IGI?

Ichnos Glenmark Innovation (IGI) was carved out as a global biotech division focused on novel biologics, including immune cell engagers and modulators. Headquartered in New York with research operations in Switzerland and India, IGI employs approximately 125 scientists and specialists dedicated to oncology and autoimmune pipelines. The core pipeline features multiple candidates at different stages, and several of them have been strategically out-licensed to international partners.

Among the most notable collaborations is ISB 880, an IL-1RAP antagonist licensed to Almirall in 2021 for autoimmune indications. Another key asset, ISB 830, a monoclonal OX40 antagonist, was licensed to Astria Therapeutics for development in atopic dermatitis and other inflammatory diseases. Both partnerships have already triggered milestone payments and provide Glenmark with future royalty streams. In the oncology vertical, the small-molecule candidate GRC 65327—targeting the immune regulator Cbl-b—has entered the regulatory pipeline in India, with Phase 1 trials expected to commence later in 2025. Notably, IGI has transitioned away from in-house manufacturing and will now rely on global CDMOs for clinical and commercial production, enabling cost efficiency and scalability as demand rises.

Is the Market Rewarding Glenmark’s Biotech Vision?

Investor sentiment has turned cautiously optimistic following the Fast Track designation of ISB 2001. On May 24, 2025, Glenmark Pharmaceuticals stock closed at ₹1,420.20, reflecting a minor dip of 0.66% despite strong earnings. However, institutional investors appear to be waiting for the next wave of clinical data, particularly from the Rapid Oral Abstract Session at the upcoming ASCO 2025 meeting. Should the presentation demonstrate consistent safety and efficacy in the expanded cohort, analysts anticipate a potential re-rating of Glenmark’s biotech credentials.

Buy-side interest has been gradually building, with foreign institutional investors reentering post-Q4 FY25 results. Domestic mutual funds remain on the sidelines, likely awaiting Phase 2 initiation or licensing events. If Glenmark successfully initiates a strategic alliance for ISB 2001 or secures large-scale funding for IGI’s development, the market could revise its current conservative stance. Until then, the company will have to rely on continued scientific validation to build investor trust.

How Is Glenmark Pharmaceuticals Positioned Among Indian Biotech Peers?

Glenmark’s biotech ambitions set it apart from most of its Indian pharmaceutical peers. Companies like Biocon have built substantial credibility in biosimilars, especially in collaboration with Mylan-Viatris and the Serum Institute. Dr. Reddy’s Laboratories and Cipla have taken smaller, more measured steps into complex generics and biologics, often via partnerships. In contrast, Glenmark’s approach centers on first-in-class innovation with the potential for global impact.

ISB 2001 is not a me-too biosimilar or reformulated molecule—it is a differentiated, high-risk, high-reward biologic asset with the potential to address one of oncology’s most challenging diseases. If Glenmark can navigate regulatory hurdles, complete clinical trials, and find the right commercialization partner, it could become India’s first homegrown biotech firm to rival mid-tier U.S. and European innovators. The implications for the broader Indian pharmaceutical industry are profound, signaling a shift from reverse-engineering to genuine discovery.

What’s Next for Glenmark’s ISB 2001 in FY26?

The next 12 months are critical. Glenmark is scheduled to present updated data from its dose-expansion cohort at the American Society of Clinical Oncology (ASCO) conference in June 2025. A follow-up presentation at the European Hematology Association (EHA) meeting later in the same month is also expected. If the clinical profile remains favorable, Glenmark is likely to initiate global Phase 2 trials in the second half of FY26. The company also expects to complete regulatory filings for ISB 2001 in Europe by late Q2 FY26, further expanding its geographic reach.

Commercialization partnerships are reportedly under discussion. The outcome of these negotiations could determine whether Glenmark Pharmaceuticals proceeds with full-scale development on its own or licenses the program to a global player. Either way, the next stage will likely require substantial capital infusion and scientific collaboration. If managed well, ISB 2001 could become Glenmark’s first biologic to surpass $500 million in potential annual sales and reposition the company as a credible biotech contender on the global stage.